{"filing":{"accession_number":"0000886163-26-000050","cik":"0000886163","ticker":"LGNYZ","company_name":"LIGAND PHARMACEUTICALS INC","form":"8-K","filing_date":"2026-09-22","report_date":"2026-09-22","primary_document":"lgnd-20260922.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/886163/000088616326000050/lgnd-20260922.htm"},"events":[{"id":34168,"run_id":31438,"accession_number":"0000886163-26-000050","anchor_item_number":"7.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"summary":"Ligand acquired royalty and milestone payment rights relating to Santen's Ryjunea® from Sydnexis for $23 million upfront. This is a material acquisition of intellectual property and economic rights—a transaction that expands Ligand's royalty portfolio and creates a new revenue stream. The press release emphasizes this as a strategic acquisition of \"the type of differentiated asset\" for Ligand's royalty aggregation business, making it a material M\u0026A activity despite being structured as a royalty rights acquisition rather than a traditional company acquisition.","company_name":"LIGAND PHARMACEUTICALS INC","ticker":"LGNYZ","filing_date":"2026-09-22","form":"8-K","submitted_at":null,"items":[{"id":37831,"accession_number":"0000886163-26-000050","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"Ligand acquired royalty and milestone payment rights relating to Santen's Ryjunea® from Sydnexis for $23 million upfront. This is a material acquisition of intellectual property and economic rights—a transaction that expands Ligand's royalty portfolio and creates a new revenue stream. The press release emphasizes this as a strategic acquisition of \"the type of differentiated asset\" for Ligand's royalty aggregation business, making it a material M\u0026A activity despite being structured as a royalty rights acquisition rather than a traditional company acquisition.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-22T11:09:38.330057+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":37831,"accession_number":"0000886163-26-000050","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"Ligand acquired royalty and milestone payment rights relating to Santen's Ryjunea® from Sydnexis for $23 million upfront. This is a material acquisition of intellectual property and economic rights—a transaction that expands Ligand's royalty portfolio and creates a new revenue stream. The press release emphasizes this as a strategic acquisition of \"the type of differentiated asset\" for Ligand's royalty aggregation business, making it a material M\u0026A activity despite being structured as a royalty rights acquisition rather than a traditional company acquisition.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-22T11:09:38.330057+00:00","company_name":"LIGAND PHARMACEUTICALS INC","ticker":"LGNYZ","filing_date":"2026-09-22"}]}